2 weeks Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates Zacks

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 9.48% and 5.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?